| Literature DB >> 26649059 |
Annie George1, Sasikala Chinnappan1, Yogendra Choudhary2, Vandana Kotak Choudhary2, Praveen Bommu2, Hoi Jin Wong1.
Abstract
The aim of the study was to explore a propriety standardized ethanolic extract from leaves of Orthosiphon stamineus Benth in improving impairments in short-term social memory in vivo, possibly via blockade of adenosine A2A receptors (A2AR). The ethanolic extract of O. stamineus leaves showed significant in vitro binding activity of A2AR with 74% inhibition at 150 μg/ml and significant A2AR antagonist activity with 98% inhibition at 300 μg/mL. A significant adenosine A1 receptor (A1R) antagonist activity with 100% inhibition was observed at 300 μg/mL. Its effect on learning and memory was assessed via social recognition task using Sprague Dawley rats whereby the ethanolic extract of O. stamineus showed significant (p < 0.001) change in recognition index (RI) at 300 mg/kg and 600 mg/kg p.o and 120 mg/kg i.p., respectively, compared to the vehicle control. In comparison, the ethanolic extract of Polygonum minus aerial parts showed small change in inflexion; however, it remained insignificant in RI at 200 mg/kg p.o. Our findings suggest that the ethanolic extract of O. stamineus leaves improves memory by reversing age-related deficits in short-term social memory and the possible involvement of adenosine A1 and adenosine A2A as a target bioactivity site in the restoration of memory.Entities:
Year: 2015 PMID: 26649059 PMCID: PMC4655036 DOI: 10.1155/2015/375837
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Adenosine receptor A2A binding assay parameters.
| Adenosine A2A | |
|---|---|
| Source | Human recombinant HEK-293 cells |
| Ligand | 0.05 |
| Vehicle | 1% DMSO |
| Incubation time/temp. | 90 minutes at 25°C |
| Incubation buffer | 50 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 2 U/mL adenosine Deaminase |
| Nonspecific ligand | 50 |
| KD | 0.064 |
|
| 7 pmole/mg protein |
| Specific binding | 85% |
| Quantitation method | Radioligand binding |
| Significance criteria | ≥50% of max stimulation |
| Reference | CGS-21680 |
Adenosine receptor A2A functional assay parameters.
| Adenosine A2A adenylyl cyclase | |
|---|---|
| Source | Human recombinant HEK-293 cells |
| Control | 0.1 |
| Vehicle | 0.40% DMSO |
| Incubation time/temp. | 10 minutes at 37°C |
| Incubation buffer | Modified Hank's balanced salt solution (HBSS) pH 7.4 |
| Quantitation method | HTRF quantitation of cAMP accumulation |
| Significant criteria for agonist | ≥50% increase in cAMP relative to NECA response |
| Significant criteria for antagonist | ≥50% inhibition of NECA-induced cAMP increase |
Adenosine receptor A1 functional assay parameter.
| Adenosine A1 | |
|---|---|
| Source | Wistar rat vas deferens |
| Control | 0.3 |
| Vehicle | 0.10% DMSO |
| Incubation time/temp. | 5 minutes at 32°C |
| Incubation buffer | KREBS pH 7.4 |
| Quantitation method | Isometric (gram changes) |
| Significant criteria for agonist | ≥50% reduction of neurogenic twitch relative to 0.3 |
| Significant criteria for antagonist | ≥50% inhibition of 0.3 |
Animal grouping according to test materials, dose, and route of administration.
| Group number | Dose level | Route | Number of animals |
|---|---|---|---|
| 1 | Vehicle control | p.o. | 10 |
| 2 | BT 00119 (200 mg/kg) | p.o. | 10 |
| 3 | BT 00119 (300 mg/kg) | p.o. | 10 |
| 4 | BT 00119 (600 mg/kg) | p.o. | 10 |
| 5 | PME 00012 (200 mg/kg) | p.o. | 10 |
| 6 | GBE 000120 (120 mg/kg) | p.o. | 10 |
| 7 | Donepezil (3 mg/kg) | i.p. | 10 |
| 8 | BT 00119 (60 mg/kg) | i.p. | 10 |
| 9 | BT 00119 (120 mg/kg) | i.p. | 10 |
Figure 1HPLC chromatograms of O. stamineus leaf ethanolic extract.
Figure 2HPLC chromatograms of reference standard compounds. The identified peaks are ombuin (3,3′,5-trihydroxy-4′,7-dimethoxyflavone), 3′-hydroxy-4′,5,6,7-tetramethoxyflavone, sinensetin, orthosiphol B, orthosiphol A, staminol A, and orthosiphonone A.
Results of in vitro adenosine A2A and adenosine A1 assays.
| Assay | Concentration ( | Inhibition (%) | IC50 ( |
|---|---|---|---|
| Adenosine A2A binding assay | 15 | 17 | 60.07 |
| 150 | 74 | ||
|
| |||
| Adenosine A2A functional assay antagonist | 3 | 14 | 51.5 |
| 30 | 26 | ||
| 300 | 98 | ||
|
| |||
| Increase in cAMP (%) | |||
| Adenosine A2A functional assay agonist | 3 | −1 | — |
| 30 | −3 | ||
| 300 | −8 | ||
|
| |||
| Adenosine A1 functional assay antagonist activity | 3 | 0 | 95.1 |
| 30 | 0 | ||
| 300 | 100 | ||
|
| |||
| Reduction in neurogenic twitch (%) | |||
| Adenosine A1 functional assay agonist activity | 3 | 5 | — |
| 30 | 12 | ||
| 300 | 29 | ||
Figure 3Response curve for adenosine A1 antagonist assay. The IC50 of adenosine A1 antagonist assay for O. stamineus ethanolic extract is 95.1 μg/mL.
Figure 4Response curve for adenosine A2A antagonist assay. The IC50 of adenosine A2A antagonist assay for O. stamineus ethanolic extract is 51.5 μg/mL.
Effect of O. stamineus (BT 00119), P. minus (PM 00012), G. biloba (GBE 00110), and donepezil on recognition index with respect to duration of interactions in social recognition test in the SD rats.
| Treatment (mg/kg) | Investigation duration (seconds) | C2 versus C1 | Recognition index (C2/C1) | |||||
|---|---|---|---|---|---|---|---|---|
| Route | First contact (C1) | Second contact (C2) 120 min after C1 | ||||||
| Mean ± SEM |
| Mean ± SEM |
|
| Mean ± SEM |
| ||
| Vehicle | p.o. | 22.00 ± 11.59 | — | 25.00 ± 13.0 | — | 0.1777 | 1.107 ± 0.20 | — |
| BT 00119 (200) | p.o. | 28.67 ± 5.36 | 0.3146 | 14.33 ± 8.51 | 0.2656 | 0.1273 | 0.5033 ± 0.24 | 0.0661 |
| BT 00119 (300) | p.o. | 57.33 ± 7.53a | 0.0315 | 14.33 ± 2.90 | 0.2348 | 0.0119b | 0.2400 ± 0.02 | 0.0068c |
| BT 00119 (600) | p.o. | 71.00 ± 7.81a | 0.0124 | 8.333 ± 1.85 | 0.1374 | 0.0051b | 0.1133 ± 0.017 | 0.0042c |
| PME 00012 (200) | p.o. | 48.67 ± 6.88 | 0.0595 | 31.00 ± 5.68 | 0.3475 | 0.1419 | 0.6833 ± 0.18 | 0.0986 |
| GBE 00110 (120) | p.o. | 52.67 ± 5.69a | 0.0382 | 33.67 ± 2.84 | 0.2759 | 0.0775 | 0.6600 ± 0.11 | 0.0651 |
| Donepezil (3) | i.p. | 30.67 ± 1.20 | 0.2492 | 18.33 ± 4.33 | 0.3266 | 0.0621 | 0.5500 ± 0.11 | 0.0593 |
| BT 00119 (60) | i.p. | 26.67 ± 4.80 | 0.3644 | 8.667 ± 5.23 | 0.1550 | 0.1801 | 0.3867 ± 0.28 | 0.0539 |
| BT 00119 (120) | i.p. | 51.00 ± 2.51a | 0.0354 | 14.00 ± 2.51 | 0.2272 | 0.0136b | 0.2733 ± 0.05 | 0.0086c |
p.o. = per oral, i.p. = intraperitoneal, and SEM = standard error mean.
a p < 0.05 indicates the significance of first contact in comparison with vehicle control for all groups.
b p < 0.05 and b p < 0.001 indicate the significance in comparing the change in activity before and after treatment.
c p < 0.01 and c p < 0.001 indicate the significant changes of RI when compared with vehicle control.